NANETS Symposium

Emerging Therapies, Biologic Discoveries, and Improved QoL on Horizon for NETs

October 21, 2017

The treatment armamentarium of neuroendocrine tumors (NETs) is expanding to potentially include novel systemic therapies, a refined understanding of genetic changes in patients with pancreatic NETs, and improvements in surgical timing and quality of life (QoL), according to Diane Reidy Lagunes, MD.

PRRT Effective and Safe as Salvage Therapy for GEP and Bronchial NETs

October 21, 2017

Tumor response rates after initial treatment with peptide receptor radionuclide therapy have proven clinical benefit; however, complete response is uncommon.

Diagnosing and Treating NET-Related Diarrhea

October 21, 2017

Determining the true nature, causes, and optimal treatment of neuroendocrine tumors is incredibly important for patients, as even though diarrhea can be a symptom of the disease, it is not always the primary cause.

Diagnosing G3 NETs and NECs

October 21, 2017

Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.

Personalizing Therapy With PRRT and Improving Imaging With SSTR-PET Brings Novel Options to NETs Landscape

October 21, 2017

Thomas Hope, MD, discusses personalizing therapy for patients with neuroendocrine tumors with Lutathera as well as the significance of somatostatin receptor PET to the treatment landscape.

Call to Action for Patient-Reported Outcome Measurements in Clinical Practice for NETs Patients

October 21, 2017

In a call to action to the neuroendocrine tumor clinical community during the 10th Annual NANETS Symposium, presenter Lesley Moody, MBA, addressed the importance of patient-reported outcomes and patient-reported outcome measurements in the everyday care of patients with NETs, beyond clinical trials.

Phase III Trial Needed to Confirm Clinical Benefit of Cabozantinib in Carcinoid and Pancreatic NETs

October 20, 2017

Encouraging results are being seen following the administration of cabozantinib (Cabometyx) in patients with carcinoid and pancreatic neuroendocrine tumors. Clinical benefit of the drug has been exhibited in patients enrolled in a prospective phase II trial, which was initiated in July 2012; however, a randomized phase III trial will be necessary for confirmation.

Managing Diarrhea in Patients With Carcinoid Syndrome

October 20, 2017

Pamela L. Kunz, MD, assistant professor of medicine (oncology), Stanford University Medical Center, discusses managing the adverse event of diarrhea in patients with carcinoid syndrome, specifically with the use of telotristat ethyl (Xermelo) during the 10th Annual NANETS Symposium.

Improving Outcomes, Value, and Data Collection in Oncology

October 20, 2017

An Abramson Cancer Center expert explains how departments can leverage informatics during the 10th Annual NANETS Symposium.

Challenges in Creating a Multidisciplinary Practice for Patients With NETs

October 20, 2017

Bringing coordinated multidisciplinary cancer treatment together into one place is ideal to improve care for patients with neuroendocrine tumors (NETs), according to David C. Metz, MD, during the 10th Annual NANETS Symposium.